Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of obeticholic acid alone or with bezafibrate in primary biliary cholangitis
MOH_2020-07-01_008520Phase 2Not yet recruiting
- Sponsor
- Intercept Pharmaceuticals, Inc
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obeticholic acid and bezafibrate in primary biliary cholangitis (PBC) (3 arms), sponsored by Intercept Pharmaceuticals, Inc. Primary endpoint: Change in alkaline phosphatase. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
obeticholic acidbezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2020-07-01_008520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-01_008520.